Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations

References

• Elshoff J-P, Cawello W, Andreas J-O, Mathy F-X, Braun M. An update on pharmacological, pharmacokinetic properties and drug–drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs. 2015;75(5):487–501.25795100
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AHV. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22(16):2398–2404.17935234
   PubMed Web of Science ®Google Scholar
• Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson’s disease. Expert Opin Pharmacother. 2009;10(4): 677–691.19239399
   PubMed Web of Science ®Google Scholar
• Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009;379(1):73–86.18704368
   PubMed Web of Science ®Google Scholar
• NEUPRO Prescribing Information. ©2015 UCB, Inc., Smyrna, GA 30080 All rights Reserv; 2015.
   Google Scholar
• Benitez A, Edens H, Fishman J, Moran K, Asgharnejad M. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson’s disease and restless legs syndrome. Ann N Y Acad Sci. 2014;1329:45–66.25145951
   PubMed Web of Science ®Google Scholar
• Kim JM, Chung SJ, Kim JW, et al; Asia Pacific Rotigotine Add-on Study Group. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study. BMC Neurol. 2015;15(1):1–9.25595849
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Poewe W, et al; SP790 Study Group. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008;7(7):595–604.18515185
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al; Rotigotine SP 709 Study Group. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med. 2008;9(3):228–239.17553743
   PubMed Web of Science ®Google Scholar
• Hening WA, Allen RP, Ondo WG, et al; SP792 Study Group. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010;25(11):1675–1683.20629075
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al; Rotigotine SP710 Study Group. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med. 2008;9(8):865–873.18753003
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–844.24434037
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf AD, Potenza MN, et al Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969–973.16831966
   PubMedGoogle Scholar
• Grinberg LT, Rueb U, Alho AT, Heinsen H. Brainstem pathology and non-motor symptoms in PD. J Neurol Sci. 2010;289(1–2):81–88.19758601
   PubMed Web of Science ®Google Scholar
• Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain. 1999;122(8):1437–1448.10430830
   PubMed Web of Science ®Google Scholar
• Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature. 1988;334(6180):345–348.2899295
   PubMed Web of Science ®Google Scholar
• German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson’s disease: computer visualization. Ann Neurol. 1989;26(4):507–514.2817827
   PubMed Web of Science ®Google Scholar
• Sullivan KL, Ward CL, Hauser RA, Zesiewicz TA. Prevalence and treatment of non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(8):545.17188922
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Evatt ML. Potential influences of complementary therapy on motor and non-motor complications in Parkinson’s disease. CNS Drugs. 2009;23(10):817–835.19739693
   PubMed Web of Science ®Google Scholar
• Güldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol. 2015;28(3):106–110.
   Google Scholar
• Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64(5):676–682.17502466
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol. 2003;60:1721–1728.14676046
   PubMedGoogle Scholar
• Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68(4):272–276.17202432
   PubMed Web of Science ®Google Scholar
• Oertel WH, Beneš H, Garcia-Borreguero D, et al Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med. 2010;11(9):848–856.20813583
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al; Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–99.21322021
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262–1267.17438216
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N, et al; SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513–520.17509486
   PubMed Web of Science ®Google Scholar
• Nomoto M, Mizuno Y, Kondo T, et al Transdermal rotigotine in advanced Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. J Neurol. 2014;261(10):1887–1893.25022939
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sullivan KL, Hauser RA. Nonmotor symptoms of Parkinson’s disease. Expert Rev Neurother. 2006;6(12):1811–1822.17181428
   PubMedGoogle Scholar
• Zesiewicz TA, Martinez-Martin P. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson’s disease: an overview. Expert Rev Neurother. 2013;13(12):1329–1342.24236902
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19(7):660–665.23557594
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–474.19375664
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al; PRIAMO Study Group. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–1649.19514014
   PubMed Web of Science ®Google Scholar
• Kassubek J, Chaudhuri KR, Zesiewicz T, et al Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol. 2014;14:42.24602411
   PubMed Web of Science ®Google Scholar
• Giladi N, Fichtner A, Poewe W, Boroojerdi B. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease. J Neural Transm. 2010;117(12):1395–1399.21080009
   PubMed Web of Science ®Google Scholar
• Pagonabarraga J, Piñol G, Cardozo A, et al Transdermal rotigotine improves sleep fragmentation in Parkinson’s disease: results of the multicenter, prospective SLEEP-FRAM study. Parkinsons Dis. 2015;2015: 1–7.
   Web of Science ®Google Scholar
• Walters AS, LeBrocq C, Dhar A, et al; International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4(2):121–132.14592342
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti DL, Garcia-Borreguero D, et al; International Restless Legs Syndrome Study Group. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria–history, rationale, description, and significance. Sleep Med. 2014;15(8):860–873.25023924
   PubMed Web of Science ®Google Scholar
• Merlino G, Serafini A, Robiony F, Valente M, Gigli GL. Restless legs syndrome: differential diagnosis and management with rotigotine. Neuropsychiatr Dis Treat. 2009;5:67–80.19557102
   PubMed Web of Science ®Google Scholar
• Inoue Y, Shimizu T, Hirata K, et al; Rotigotine Trial Group. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Med. 2013;14(11):1085–1091.24055212
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster K, Kohnen R, Schollmayer E, Möller JC, Oertel WH. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord. 2004;19(12):1432–1438.15390055
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Grote L, et al; CALDIR Study Group. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord. 2007;22(5):696–703.17274039
   PubMed Web of Science ®Google Scholar
• Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19(3):205–213.8723377
   PubMed Web of Science ®Google Scholar
• Beneš H, García-Borreguero D, Ferini-Strambi L, Schollmayer E, Fichtner A, Kohnen R. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med. 2012;13(6): 589–597.22503658
   PubMed Web of Science ®Google Scholar
• Oertel W, Trenkwalder C, Beneš H, et al; García-Borreguero D; SP710 Study Group. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10(8):710–720.21705273
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Kohnen R, Silber MH, et al The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675–684.23859128
   PubMed Web of Science ®Google Scholar
• Högl B, Oertel WH, Stiasny-Kolster K, et al Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol. 2010;10:86.20920156
   PubMed Web of Science ®Google Scholar
• Allen R, Oertel W, Walters A, et al Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression Severity Scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire. Sleep Med. 2013;14(12):1375–1380.24246378
   PubMed Web of Science ®Google Scholar
• Benhaddi HGH. Cost utility analysis of rotigotine transdermal patch in early stage Parkinson’s disease in Scotland. Poster Presented at: ISPOR 13th Annu Eur Congr Prague; 2010; Czech Republic: 1.
   Google Scholar
• Aguirre A, Benitez ABH. Cost effectiveness of rotigotine transdermal patch in patients with advanced Parkinson’s disease in Mexico. Poster Presented at: ISPOR 13th Annu Eur Congr Prague; 2010; Czech Republic: 1.
   Google Scholar
• Mizuno Y, Nomoto M, Hasegawa K, et al; Rotigotine Trial Group. Rotigotine vs ropinirole in advanced stage Parkinson’s disease: a double-blind study. Parkinsonism Relat Disord. 2014;20(12):1388–1393.25455692
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22–e33.19514806
   PubMed Web of Science ®Google Scholar
• Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord. 2005;20(11):1502–1507.16037924
   PubMed Web of Science ®Google Scholar
• Tarrants ML, Denarié MF, Castelli-Haley J, Millard J, Zhang D. Drug therapies for Parkinson’s disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother. 2010;8(4): 374–383.20869623
   PubMed Web of Science ®Google Scholar
• Schnitzler A, Leffers KW, Häck HJ. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson’s disease. Parkinsonism Relat Disord. 2010;16(8):513–516.20605106
   PubMed Web of Science ®Google Scholar
• Ghys L, Surmann E, Whitesides J, Boroojerdi B. Effect of rotigotine on sleep and quality of life in Parkinson’s disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin Pharmacother. 2011;12(13):1985–1998.21790503
   PubMed Web of Science ®Google Scholar
• Sieb JP, Themann P, Warnecke T, et al Caregivers’ and physicians’ attitudes to rotigotine transdermal patch versus oral Parkinson’s disease medication: an observational study. Curr Med Res Opin. 2015;31(5): 967–974.25772231
   PubMed Web of Science ®Google Scholar
• Mu H, Ma P, Zhang W, Wang A, Wang W, Sun K. Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies. Int J Nanomedicine. 2015;10:633–644.25609965
   PubMed Web of Science ®Google Scholar